A detailed history of First National Advisers, LLC transactions in Amgen Inc stock. As of the latest transaction made, First National Advisers, LLC holds 21,731 shares of AMGN stock, worth $7.43 Million. This represents 0.85% of its overall portfolio holdings.

Number of Shares
21,731
Previous 20,821 4.37%
Holding current value
$7.43 Million
Previous $5.81 Million 5.49%
% of portfolio
0.85%
Previous 0.87%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 28, 2025

BUY
$271.18 - $309.22 $246,773 - $281,390
910 Added 4.37%
21,731 $6.13 Million
Q2 2025

Aug 13, 2025

BUY
$262.28 - $309.85 $60,848 - $71,885
232 Added 1.13%
20,821 $5.81 Million
Q1 2025

May 07, 2025

BUY
$258.59 - $327.36 $583,379 - $738,524
2,256 Added 12.31%
20,589 $6.41 Million
Q4 2024

Feb 10, 2025

BUY
$258.78 - $328.31 $74,528 - $94,553
288 Added 1.6%
18,333 $4.78 Million
Q3 2024

Oct 15, 2024

BUY
$309.38 - $337.38 $325,467 - $354,923
1,052 Added 6.19%
18,045 $5.81 Million
Q2 2024

Aug 13, 2024

BUY
$262.75 - $319.31 $1.55 Million - $1.89 Million
5,914 Added 53.38%
16,993 $5.31 Million
Q1 2024

May 15, 2024

BUY
$268.87 - $324.56 $436,913 - $527,410
1,625 Added 17.19%
11,079 $3.15 Million
Q4 2023

Feb 08, 2024

BUY
$255.7 - $288.46 $1.27 Million - $1.43 Million
4,965 Added 110.6%
9,454 $2.72 Million
Q3 2023

Nov 09, 2023

BUY
$218.65 - $271.46 $981,519 - $1.22 Million
4,489 New
4,489 $1.21 Million
Q1 2023

May 10, 2023

SELL
$225.79 - $275.2 $36,126 - $44,032
-160 Reduced 16.05%
837 $202,000
Q4 2022

Feb 09, 2023

BUY
$229.03 - $291.01 $27,025 - $34,339
118 Added 13.42%
997 $261,000
Q3 2022

Nov 04, 2022

BUY
$224.46 - $253.15 $197,300 - $222,518
879 New
879 $198,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $183B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track First National Advisers, LLC Portfolio

Follow First National Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First National Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on First National Advisers, LLC with notifications on news.